Latest Conference Articles

Long-Term Data Confirms One-Year of Adjuvant Trastuzumab as Standard of Care

Eight-year follow-up data from the phase III HERA trial has confirmed that 1-year of adjuvant trastuzumab should remain the treatment standard in women with HER2-positive early-stage breast cancer.

Dr. Yarnold on Hypofractionation in the START Trials

John Yarnold, MBBS, from The Institute of Cancer Research in London, discusses results from the START trials that examined hypofractionated radioatherapy for women with early breast cancer.

Adjuvant Bevacizumab Falls Short in Triple-Negative Breast Cancer

Patients with triple-negative breast cancer had no statistically significant improvement in disease-free survival when they received adjuvant treatment with chemotherapy plus 1 year of bevacizumab.

Dr. Leyland-Jones Discusses the Phase III HERA Trial

Brian Leyland-Jones, MBBS, PhD, discusses results from the phase III HERA trial that compared 2 years of adjuvant trastuzumab to the standard 1 year in HER2-postive early-stage breast cancer.

Study Shows Eribulin Not Superior to Capecitabine in Previously Treated Metastatic Breast Cancer

Eribulin mesylate failed to show a statistically significant survival benefit compared with capecitabine in women with previously treated metastatic breast cancer.

Genetic Analysis Identifies New Targets in Triple-Negative Breast Cancer

Patients with triple-negative breast cancer who have residual disease after receiving neoadjuvant chemotherapy have a series of genetic alterations that are clinically targetable and may warrant further study.

Dr. Bhalla on Sensitizing TNBC to PARP Inhibitors and Cisplatin

Kapil N. Bhalla, MD, from the University of Kansas Cancer Center, describes an in vivo study that examined treatment with histone deacetylase inhibitors in triple-negative breast cancer cells.

Dr. Aebi on Adjuvant Chemo in Recurrent Breast Cancer

Stefan Aebi, MD, from the Luzerner Kantonsspital, Switzerland, discusses findings from the CALOR trial that examined the administration of adjuvant chemotherapy for women recurrent breast cancer.

HDAC Inhibition Appears to Sensitize Triple-Negative Breast Cancer Cells to Certain Treatments

Preliminary research suggests that in-vitro exposure to an HDAC inhibitor may sensitize triple-negative breast cancer cells to treatment with a PARP inhibitor and cisplatin.

Adjuvant Chemotherapy Improves Survival in Women With Recurrent Breast Cancer

Adjuvant chemotherapy improved survival rates in women with isolated local or regional breast cancer recurrence, according to results from the CALOR trial.

Higher Dose of Fulvestrant Associated With Improved Survival in Advanced Breast Cancer

Postmenopausal women with advanced estrogen receptor–positive breast cancer lived longer when they received a 500-mg dose of fulvestrant as compared with a 250-mg dose.

New Agent Significantly Improves Progression-Free Survival in Patients With Advanced ER+ Breast Cancer

Combining the investigational PD 0332991 with letrozole as first-line therapy extended progression-free survival in women with advanced estrogen-receptor positive breast cancer.

Sentinel Lymph Node Surgery After Chemotherapy Shows Accuracy in Nodal Staging in Breast Cancer

Sentinel lymph node surgery may provide a less-invasive alternative to axillary lymph node dissection for nodal staging in node-positive breast cancer.

Adjuvant Tamoxifen for 10 Years Better Than 5 Years in ER-Positive Breast Cancer

Extending the duration of adjuvant tamoxifen treatment to 10 years was more effective than the standard 5 years of treatment in protecting against recurrence and death among women with ER+ breast cancer.

Dr. Boughey on Reducing False Negatives in SLN Surgery

Judy C. Boughey, MD, from the Mayo Clinic in Rochester, MN, discusses surgical techniques examined in the Z1071 study that could help minimize the false negative rates experienced with SLN surgery.

Dr. Finn on PD 0332991 Plus Letrozole in Breast Cancer

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, describes results from a phase II study that examined PD 0332991 in combination with letrozole for women with metastatic ER-positive breast cancer.

Recently Approved Therapies Bring New Understanding in Management of Prostate Cancer

After many years of treating patients with advanced prostate cancer the same way, a host of new drug approvals has not only changed the way urologists manage prostate cancer but their understanding of the disease as well.

Dr. Rotkowitz Describes Challenges Facing Immunotherapy

Michael Rotkowitz, MD, says that one of the main challenges and a leading goal of immunotherapy research is measuring response to justify the administration.

Meeting Addresses Challenges Facing Urology Groups in Cancer Care

The 2012 LUGPA Annual Meeting is expected to gather more than 100 urology groups to discuss administrative, technological, regulatory, and medical challenges facing practices.

Dr. Freedland on Treating Early-Stage Prostate Cancer

Stephen J. Freedland, MD, from Duke University School of Medicine, discusses the complications faced when treating men with early-stage prostate cancer.

Tracking the Oncology Pipeline: Developments From ESMO

The latest research on several investigational cancer therapies was presented at the European Society for Medical Oncology 2012 Congress.

Photos From the 2012 NCONN Conference

Photos from the 2012 National Coalition of Oncology Nurse Navigators' (NCONN) annual conference that was held at the Gaylord Opryland Hotel from October 4th to 6th, in Nashville, Tennessee.

New Metastatic Melanoma Therapies Create Hope for Patients, Key Role for Oncology Nurses

The incidence of melanoma, the deadliest of all skin cancers, is quickly rising, and the disease is responsible for more than 8000 deaths each year.

Opportunity Knocks: New ACoS Standard Requires Navigation Process in Place by 2015

Facilities seeking Commission on Cancer accreditation now need to have a patient navigation process in place by 2015.

Beth DuPree, MD, Updates Navigators on Breast Cancer Treatments

Updates on breast cancer risk factors, screening methods, and treatments for the nurse navigators who are guiding patients from diagnosis to treatment and, hopefully, through survivorship.

Cristi Radford on the Nurse Navigator's Role in Genetic Counseling

Cristi Radford, a Certified Genetic Counselor, explains the multifaceted role that oncology nurse navigators play in the genetic counseling process.

Dr. Cohen on the Cabozantinib Dosage and Tolerability

Ezra Cohen, MD, from the University of Chicago Medical Center, discusses the impact of cabozantinib's dose size on tolerability.

Photos From the European Society for Medical Oncology Congress

Photos from the 2012 European Society for Medical Oncology (ESMO) congress, held at the Austria Center Vienna from September 28 to October 2, in Vienna, Austria.

In Refractory GIST, Regorafenib Delays Disease Progression Across All Subgroups

Regorafenib significantly delays disease progression in virtually all subgroups of patients with GIST in the second-line setting, and may even confer benefits when continued after progression.

Long-Term Data Show Significant Improvement in Survival With Ipilimumab in Melanoma

Nearly twice as many patients with metastatic melanoma who received a combination of ipilimumab and dacarbazine were alive after four years, suggesting that ipilimumab has long-term survival benefits.